SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending following the release of strong earnings, with discussions centered on revenue growth and future guidance. Despite positive reports, the stock experiences volatility, leading to community debates about profit-taking versus long-term potential. Some investors express frustration over the stock's typical post-earnings dip, while others see it as a buying opportunity ahead of potential catalysts like interest rate cuts and inclusion in the S&P 500.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

WULF is trending due to discussions around a potential short squeeze, fueled by high short interest and analyst price target increases; community members are debating whether the stock will break through resistance levels and initiate a significant upward move. The Google-backed AI contract is a key catalyst, with many believing shorts will soon need to cover their positions.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending due to NVIDIA's significant equity investment, sparking community excitement about a potential strategic partnership focused on enhancing 5G and 6G RAN software. The community is actively discussing the potential impact on Nokia's AI and cloud networking presence, as well as speculation on whether this could lead to further acquisitions. Some analysts are also upgrading their rating for the stock as Nokia transforms into an AI data center play.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI CRYPTO is gaining traction as a community-driven token on the Solana blockchain, with many highlighting its potential as $SOL approaches all-time highs. Community members are emphasizing the 'We're All Gonna Make It' ethos, viewing it as more than just a meme. Speculation is building around the possibility of a significant breakout.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending due to a recent partnership with OpenAI to integrate its payment platform into ChatGPT, potentially revolutionizing AI-driven commerce. The community is actively discussing the positive implications of this deal, combined with an earnings beat and the introduction of a new dividend, which could drive significant growth and investor interest. Some are speculating whether the stock will return to prior levels.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is trending due to recent earnings and forward guidance, sparking discussions around cost-saving measures like job cuts and their impact on long-term growth. The community is weighing the positive signs against concerns about declining import volumes and potential dividend cuts. Bullish investors are eyeing a run to higher price targets, while bears anticipate further declines.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific is trending due to ongoing discussions around its proposed merger with CoreWeave, with a shareholder vote approaching. The community is divided, debating whether the all-stock deal undervalues CORZ, especially given its AI infrastructure potential and comparisons to peers like $APLD and $IREN. Some traders believe a rejection of the deal could lead to a surge in CORZ's price, while others fear a collapse, highlighting the uncertainty surrounding the company's future and management's strategy.

ETHZilla Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palm Beach, FL.

ETHZilla Corp

ETHZilla Corporation

ETHZ is trending as traders discuss the company's recent decision to sell Ethereum to fund share buybacks and the upcoming reverse stock split. The community is debating the company's strategy, with some expressing concerns about potential dilution and others pointing to the stock's discount to net asset value and potential for a short squeeze. Bullish sentiment is building as some note recent institutional investment, a low float, and potential for further gains should Ethereum prices increase.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending as investors react to earnings results and forward guidance, with the community debating the impact of the numbers. Bullish sentiment revolves around potential breakouts and long-term growth, while bears point to margin concerns and possible manipulation.

WISeKey International Holding Ltd. is a cybersecurity company, which engages in offering digital security technology solutions. The firm operates through the Internet of Things (IoT), and Managed Public Key Infrastructure (mPKI) segments. The IoT segment refers to the design, manufacturing, sales and distribution of microprocessors operations. The mPKI segment includes all operations relating to the provision of secured access keys, authentication, signing software, certificates and digital security applications. The company was founded by Joao Carlos Creus Moreira and Philippe Doubre in 1999 and is headquartered in Zug, Switzerland.

WISeKey International Holding Ltd - ADR

WISeKey is trending as traders discuss its potential, low float, and connection to the quantum computing sector. Community members highlight its relationship with $LAES and the upcoming satellite launch as potential catalysts. Some traders speculate about a short squeeze and a possible return to higher price levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>ADX-629 was administered orally for one month in four patients with mild to moderate alcohol-associated hepatitis in the study.</li><li>Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation, the company said.&nbsp;</li><li>The company has, however, &nbsp;now discontinued clinical development of ADX-629 pending further investigator-sponsored clinical testing in Sjögren-Larsson Syndrome.&nbsp; &nbsp;</li></ul>Aldeyra Therapeutics, Inc. (ALDX) on Tuesday announced that its experimental drug candidate ADX-629 demonstrated statistically significant improvement in liver function in patients with alcohol-associated hepatitis in a mid-stage trial.ADX-629 was administered orally for one month in four patients with mild to moderate alcohol-associated hepatitis in the study. Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-announces-positive-results-phase-2-clinical">said.</a>No serious adverse events were reported in the trial, the company noted. Furthermore, no adverse events were deemed related to its experimental drug, it added.<h2 class="st-heading-2">Plans Ahead</h2>The company has, however, &nbsp;now discontinued clinical development of ADX-629 pending further investigator-sponsored clinical testing in Sjögren-Larsson Syndrome, a rare genetic disorder.CEO Todd C. Brady said that the company will share details of the recent trial in the future and will now focus its pipeline on ADX-248 and ADX-246 for the treatment of immune-mediated diseases.While ADX-248 is being studied in the treatment of metabolic inflammation, including obesity and hypertriglyceridemia, ADX-246 is being studied for the treatment of dry form of age-related macular degeneration.Aldeyra is committed to developing a robust pipeline of novel therapeutics in a fiscally prudent manner to maintain growth, the CEO noted.The company now expects cash, cash equivalents, and marketable securities to provide operational runway into the second half of 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ALDX">ALDX stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.ALDX stock is down by 0.5% this year and by about 12% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-registrations-slumped-nearly-19-percent-in-eu-in-september-despite-rising-ev-demand/cLGjW7LR3HL">Tesla Registrations Slumped Nearly 19% In EU In September Despite Rising EV Demand</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Aldeyra Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Aldeyra Reports Positive Mid-Stage Data For Liver Drug, Discontinues Further Development

Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation in the study, the company said. 

Equity

Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced...

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics

CPRX, ZVRA, TBPH, ALDX, and LRMR shine amid tariff threats, thanks to strong pipelines, demand, and rising earnings estimates.

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.

Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Aldeyra Therapeutics (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Are Medical Stocks Lagging  Amgen (AMGN) This Year?

Here is how Amgen (AMGN) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.

Shares of Aldeyra Therapeutics, Inc. (ALDX) slumped nearly 71% on Thursday morning after it <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-receives-complete-response-letter-us-food-0">said</a> that the U.S. Food and Drug Administration (FDA) said the company’s investigational drug candidate reproxalap failed to demonstrate efficacy in treating ocular symptoms associated with dry eyes.The FDA told the company to resubmit its application for reproxalap and called upon the company to conduct “at least one additional adequate and well-controlled study” to demonstrate the drug’s positive effect on treating ocular symptoms of dry eye.The FDA, however, identified no manufacturing or safety issues with reproxalap, the company said.Aldeyra first submitted an application to the FDA for reproxalap in November 2022, but the agency asked for more trials. The company subsequently resubmitted its application in October 2024.Aldeyra Therapeutics CEO Todd C Brady said the company looks forward to a potential application resubmission by mid-year 2025, pending positive results from ongoing clinical trials and discussions with the FDA.On Stocktwits, retail investor sentiment about Aldeyra jumped further into the ‘extremely bullish’ territory (96/100), while message volume remained ‘extremely high’ over the past 24 hours.<figure class="image"><img style="aspect-ratio:649/156;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_03_at_10_14_30_AM_png_cb23178c6c.webp" alt="ALDX's Sentiment Meter and Message Volume as of 10:10 a.m. ET on April 3, 2025 | Source: Stocktwits" width="649" height="156"><figcaption>ALDX's Sentiment Meter and Message Volume as of 10:10 a.m. ET on April 3, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the dip is a good opportunity to buy, highlighting the company’s cash balance. Aldeyra reported cash, cash equivalents, and marketable securities of $101 million as of the end of 2024.<stembedurl>https://stocktwits.com/Pizza_guy/message/610251728</stembedurl>Another user, however, speculated the company may be facing bankruptcy.<stembedurl>https://stocktwits.com/jacobs0009/message/610251451</stembedurl><a href="https://stocktwits.com/symbol/ALDX">Aldeyra shares</a> are down by over 70% this year and by over 60% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/poni-ai-gets-robotaxi-testing-permit-in-luxembourg/chf7R7QRbe0">Pony AI Stock Draws Investor Attention On Robotaxi Testing Permit In Luxembourg: Retail Stays Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Aldeyra Stock Slumps After FDA Says Drug Candidate For Dry Eyes Treatment Failed To Show Efficacy – Retail Stays Optimistic

Aldeyra Therapeutics CEO Todd C Brady said the company looks forward to a potential application resubmission by mid-year 2025, pending positive results from ongoing clinical trials and discussions with the FDA.

Aldeyra Therapeutics to Participate in Oppenheimers 35th Annual Healthcare Life Sciences Conference

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today...

Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical...

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Aldeyra Therapeutics Inc

Will Meta ($META) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Meta Platforms Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

ALDX
Aldeyra Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ALDX News

ALDXAldeyra Therapeutics Inc